ASCENTAGE PHARMA’S LISAFTOCLAX GRANTED BREAKTHROUGH THERAPY DESIGNATION IN CHINA FOR TREATMENT-NAÏVE CLL/SLL

Reuters · 1d ago

Please log in to view news